Promising Trials in DCIS
Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses two ongoing trials that look promising for the treatment of patients with DCIS.
Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses two ongoing trials that look promising for the treatment of patients with DCIS.
Clinical Pearls:
- Patients with HER2/neu-positive DCIS who were being treated with trastuzumab showed a significant immune response to HER2/neu types of cancer cells, according to an MD Anderson study
- A vaccine comprised of stimulated monocytes and immune cells from the patient has also shown promising results
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
